Early Evidence Generation Planning goes beyond clinical trials—it includes RWE, external controls, endpoint validation, and more. This webinar explores how to assess needs early and build a tool-driven, integrated evidence plan for regulatory and HTA success.
Register here

The European JCA is already a reality for oncology and ATMP submissions—and other drugs will follow soon. It won’t replace national HTAs, but adds another layer of requirements.

Learn what’s needed for early JCA planning, from PICO scoping to comparative evidence options.

Register here